Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Nintedanib Formulations in Healthy Males
NCT02182193Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2006
- Primary completion
- Nov 2006
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of nintedanib in idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity at 48 hours and Maximum observed plasma concentration at 48 hours. Started Sep 2006; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02182193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182193.